Covalon Technologies (OTCMKTS:CVALF) Issues Earnings Results

Covalon Technologies (OTCMKTS:CVALF) announced its quarterly earnings results on Tuesday. The company reported $0.01 earnings per share (EPS) for the quarter, Zacks reports. Covalon Technologies had a negative net margin of 2.94% and a negative return on equity of 4.40%.

Covalon Technologies Stock Performance

CVALF opened at $2.30 on Wednesday. Covalon Technologies has a one year low of $0.74 and a one year high of $3.08. The company has a market capitalization of $63.02 million, a PE ratio of -76.64 and a beta of -0.27. The stock’s fifty day moving average is $2.51 and its 200-day moving average is $2.19.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.